Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

57.99 +3.84 (+7.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,989,679
Open 54.29
Bid (Size) 58.00 (1)
Ask (Size) 58.09 (1)
Prev. Close 54.15
Today's Range 54.17 - 58.71
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Both competitors have promising lead programs, and enough cash, too. 
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat

Performance

YTD
+217.23%
+217.23%
1 Month
+2.86%
+2.86%
3 Month
-20.38%
-20.38%
6 Month
+168.97%
+168.97%
1 Year
+262.89%
+262.89%

More News

Read More
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Unusual Options Activity For June 25
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $600 Today
Via Benzinga
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Via The Motley Fool
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Via The Motley Fool
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.